A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of a Single Dose of Lanadelumab Administered Subcutaneously in Healthy Adult Japanese Subjects and Matched Healthy Adult Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Lanadelumab (Primary)
- Indications Diabetic macular oedema; Hereditary angioedema
- Focus Pharmacokinetics
- Sponsors Shire
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.